List view / Grid view
Algenuity, based in Stewartby, Bedfordshire, is celebrating the successful launch of the MicroalgaE as Renewable Innovative green cell facTories project, MERIT, a three-year ERA CoBioTech project financed under the Horizon 2020 programme...
The FDA has approved Epidiolex oral solution for the treatment of seizures associated with two rare and severe forms of epilepsy...
Novel biomarker identified those with improved progression-free and overall survival...
Device can deliver drugs, proteins and stem cells directly to diseased tissue...
Results from a pivotal trial of a new HIV therapy, show that PRO 140 is an effective, long-acting therapeutic for previously treated HIV-1 infected patients...
Scientists developed monoclonal antibody from Ebola survivor...
The FDA has approved the use of Prolia for the treatment of glucocorticoid-induced osteoporosis (GIOP) in men and women at high risk of fracture...
Researchers hope immunotherapy will prevent against overactive immune response...
The FDA has approved Aimovig for the preventive treatment of a migraine in adults. The treatment is given by once-monthly self-injections...
Discovery of a pathway linking Alzheimer's disease and Type 2 diabetes leads to new strategies to preserve brain health...
A potential alternative to antibiotics, protein-coated beads block bacteria from binding host cells...
The Directive on Falsified Medicines (FMD, or Directive 2011/62/EU amending Directive 2001/83/EC) and its supplementing Delegated Regulation (DR 2016/161) aim to improve patient safety by preventing falsified medicines from entering the legal supply chain...
Over 12 months ago, the European Union delegated regulation that supplements the Falsified Medicines Directive (FMD) was published in the Official Journal of the European Union, starting the countdown to the deadline of 9 February 2019, when most EU member-states, and three non-members currently, are expected to have implemented all…
Biological products, usually referred to as biologics, constitute a significant segment of pharmaceuticals in development. Biologics include therapeutic proteins, antibody drugs, antibody-drug conjugates (ADCs), vaccines, carbohydrates drugs, blood and tissue-derived pharmaceuticals, gene therapies, even live cells and tissues...
A defining characteristic of inhaled drug delivery is variability in the dose received by the patient, as a result of physiology, for example, or the technique applied during use. This variability directly affects clinical outcomes so reducing it to a minimum is an important goal for the industry...
